Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
SD55-TSLC1
- Development stage
- Preclinical
- Lead developer
- Zhejiang Sci-Tech University
- Modality
- Oncolytic Viruses → Oncolytic Therapeutics, Gene Therapies
- Administration
- Intra-tumoral
01
Overview
SD55-TSLC1 is a survivin-regulated oncolytic adenovirus armed with the TSLC1 gene (tumor suppressor in lung cancer-1/cell adhesion molecule 1) developed for cancer therapy. Its mechanism targets cancer cells via two main actions: agonism of CADM1 (cell adhesion molecule 1, also known as TSLC1) and inhibition of survivin (baculoviral IAP repeat-containing protein 5). The selectivity comes from the survivin promoter, which is more active in cancer cells (particularly hepatocellular carcinoma) than in normal cells. Upon infection, SD55-TSLC1 overexpresses TSLC1 in tumor cells, activating caspase-mediated apoptosis pathways, leading to selective tumor cell death while sparing normal tissue. Preclinical studies show SD55-TSLC1 inhibits liver cancer growth both in vitro and in vivo. The drug was developed by Zhejiang Sci-Tech University for neoplasms, mainly hepatocellular carcinoma, and is currently at the preclinical development stage[1][3][5].
- Other names
- Ad.SP-E1A-E1B((Δ55))-TSLC1
02
Targets
CADM1 (Cell adhesion molecule 1)
Beyond the preview
Go deeper on SD55-TSLC1.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on SD55-TSLC1.